



**DRUG DEVELOPMENT TOOL
21CC Transition
DDT COA #000049**

Dan Turner MD, PhD
Director, Pediatric Gastroenterology Unit
Shaare Zedek Medical Center
P.O.B 3235
Jerusalem 91031; Israel

Anne M. Griffiths MD
Head, Division of Pediatric Gastroenterology Hepatology and Nutrition,
SickKids Hospital
Northbridge Financial Corporation Chair in IBD
Professor of Pediatrics
University of Toronto
555 University Avenue. Toronto, Canada M5G1X8

Dear Drs Turner and Griffiths:

Thank you again for agreeing to continue your ongoing clinical outcome assessment (COA) development effort under the process articulated in section 507 of the Federal Food, Drug, and Cosmetic Act as added by the 21st Century Cures Act (section 507 process). The section 507 process includes three submission types; 1) a Letter of Intent (LOI), 2) a Qualification Plan (QP), and 3) a Full Qualification Package (FQP).

As part of this transition to the section 507 process, the next step for your project, DDT COA #000049: Pediatric Inflammatory Crohn's MRE Index (PICMI), would be the development of a QP. The QP is a submission that was not part of the legacy process. You may view the COA Qualification Plan outline at:
www.fda.gov/media/123245/download.

Under the new process, all three stages are mandatory and all projects undergoing qualification must progress through the stages sequentially.

Please contact the CDER COA Qualification Program at COADDTQualification@fda.hhs.gov should you have any questions (refer to DDT COA #000049).

Sincerely,

Kimberly Chiu, PharmD
Regulatory Project Manager
Clinical Outcome Assessments Staff
Office of New Drugs
Center for Drug Evaluation and Research